- Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial
- Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN
- Additional abstracts to be presented include atrasentan’s mechanism to block mesangial cell injury and the pathogenic transcriptional networks driving IgAN progression in a translational model, as well as a systems nephrology framework for the molecular classification of chronic kidney disease to fuel Chinook's precision medicine strategy through the Evotec collaboration
- Chinook to host investor conference call and webcast on May 20, 2022 to review and discuss presented abstracts
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the 59th ERA Congress from May 19 – 22, 2022, both virtual and live in Paris, France. Two abstracts will be delivered as free communications (15 minute live oral presentations) and three abstracts will be delivered as mini-oral presentations (5 minute pre-recorded presentations).
Chinook will host a live conference call and webcast on Friday, May 20, 2022 at 4:15 pm EDT to review and discuss the abstracts. Members of the Chinook executive team will be joined by Dr. Muh Geot Wong, associate professor of nephrology at Concord Repatriation General Hospital at University of Sydney in Sydney, Australia and Dr. Jonathan Barratt, Mayer Professor of Renal Medicine at University of Leicester in Leicester, UK.
Free Communications:
| Abstract Title: | Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study |
| Presenting Author: | Muh Geot Wong, Ph.D., Concord Repatriation General Hospital at University of Sydney |
| Session Title: | Recent advances in the treatment of IgAN |
| Session Time: | Friday, May 20th at 4:15 – 4:30 pm CEST |
| Abstract Title: | A Systems Nephrology Framework for the Molecular Classification of Chronic Kidney Disease |
| Presenting Author: | Tobias Bohnenpoll, Ph.D., Evotec SE |
| Session Title: | Classification of chronic kidney disease |
| Session Time: | Friday, May 20th at 1:00 – 1:15 pm CEST |
Mini-oral Presentations:
| Abstract Title: | Updated Interim Results of a Phase 1/2 Study to Investigate the Safety, Tolerability, |
| Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA | |
| Nephropathy | |
| Presenting Author: | Jonathan Barratt, Ph.D., F.R.C.P., University of Leicester & Leicester General Hospital, Leicester, |
| UK | |
| Session Title: | Glomerulonephritis |
| Session Time: | Thursday, May 19th at 8:00 am – 12:45 pm CEST |
| Abstract Title: | Selective Endothelin A Receptor Antagonist Atrasentan Attenuates Mesangial Cell Injury, |
| Proteinuria and Intra-Renal Proliferative, Inflammatory and Fibrotic Transcriptional Networks | |
| in a Rat Model of Mesangioproliferative Glomerulonephritis | |
| Presenting Author: | Eric Olson, Ph.D., Chinook Therapeutics |
| Session Title: | Glomerulonephritis |
| Session Time: | Thursday, May 19th at 8:00 am – 12:45 pm CEST |
| Abstract Title: | A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and |
| Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy | |
| Presenting Author: | Jonathan Barratt, Ph.D., F.R.C.P., University of Leicester & Leicester General Hospital, Leicester, |
| UK | |
| Session Title: | Glomerulonephritis |
| Session Time: | Thursday, May 19th at 8:00 am – 12:45 pm CEST |
For more information on these and other abstracts, please visit the 59th ERA Congress website.
Investor Conference Call Details
To access the call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and provide the Conference ID 9428716 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding the advancement of its products and the timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials of our existing product candidates or those developed as part of the Evotec collaboration, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
